Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an improved version, and the contract ensuring access to this molecule has expired.

Conditions

Ovarian Cancer

Interventions

DRUG: AsiDNA
DRUG: Niraparib
DRUG: Olaparib
DRUG: Rucaparib

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris